You are here
Michael Raphael Tadross
Assistant Professor of Biomedical EngineeringDr. Tadross joined the Duke Department of Biomedical Engineering as an assistant professor on July 1, 2017.
His lab develops technologies to rapidly deliver drugs to genetically defined subsets of cells in the brain. By using these reagents in mouse models of neuropsychiatric disease, his group is mapping how specific receptors on defined cells and synapses in the brain give rise to diverse neural computations and behaviors. The approach leverages drugs currently in use to treat human neuropsychiatric disease, facilitating clinically relevant interpretation of the mapping effort.
Dr. Tadross received his B.S. degree in Electrical & Computer Engineering at Rutgers University, an M.D./Ph.D. degree in Biomedical Engineering at the Johns Hopkins School of Medicine, and completed his postdoctoral study in Cellular Neuroscience at Stanford University. He began his independent research program as a fellow at the HHMI Janelia Research Campus.
Appointments and Affiliations
- Assistant Professor of Biomedical Engineering
- Assistant Professor in Neurobiology
- Email Address: firstname.lastname@example.org
- Ph.D. Johns Hopkins University, 2009
- M.D. Johns Hopkins University, 2009
Our goal is to bridge the gap between the study of brain as a computational device and the search for novel neuropathological treatments. We develop technologies to manipulate molecules, cells, and synapses in the brain, and deploy these reagents in mouse models of disease.
- BME 244L9: Quantitative Physiology with Biostatistical Applications
- BME 244L: Quantitative Physiology with Biostatistical Applications
- BME 590: Special Topics in Biomedical Engineering
- BME 899: Special Readings in Biomedical Engineering
In the News
- Michael Tadross: Targeting Neuropharmacology with Molecular GPS Technologies (Nov 7, 2017 | Pratt School of Engineering )
- Homing System Delivers Drugs To Specific Neurons (Apr 7, 2017 | Pratt School of Engineering )
- Michael Tadross: Targeting Neuropharmacology with Molecular GPS Technologies (Nov 1, 2016)